Given that high doses of anti-CD3/CD28 treatment downregulated the expression of CD27 and CD28 (figure 5A, B), we postulated that lowering TCR stimulation—below a level that does not trigger DP to DN transition—would be crucial to maintain constantly high levels of these costimulatory molecules throughout Temra differentiation during tumor progression. This evidence concerns the gene CD28 and neoplasm.